

Corporate off : 601, Proxima, Plot No.19, Sector- 30 (A), Vashi, Navi Mumbai- 400705
Regd. off. : W-34, & 34/1, MIDC, Taloja, Dist.-Raigad, Maharashtra (India) 410208.
Tel. : 91 22 67944000, **Fax :** 91 22 - 67 944 001, **Email-** info@sharonbio.com
www.sharonbio.com. CIN NO. L24110MH1989PLC052251



November 11, 2020

To,
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.
Fax: 022-22723121

To,
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1, G Block,
Bandra - Kurla Complex, Bandra (East),
Mumbai - 400 051.
Fax: 022 -26598237/38

Ref.:- Scrip Code -532908

Scrip ID-SHARONBIO

Sub: Un- audited Financial Results for the quarter and half year ended September 30, 2020

Dear Sir/Madam,

Pursuant to Regulation 33 of SEBI (Listing Obligations Disclosure Requirement) Regulations, 2015, the following documents are enclosed:

- Un- Audited financial results for the quarter and half year ended September 30, 2020
- Limited Review Report for the quarter and half year ended September 30, 2020

The said results are being uploaded on the website of the Company, i.e www.sharonbio.com

The meeting commenced at 4.30 pm and concluded at 6 pm.

This is for your information and record.

Thanking You,

Yours faithfully,

For **Sharon Bio-Medicine Limited**

Kaushik Banerjee
Digitally signed by
Kaushik Banerjee
Date: 2020.11.11
18:08:55 +05'30'

Kaushik Banerjee
Chief Executive Officer

Encl.: As Above

Caring for relationships

Sharon Bio - Medicine Limited
Statement of Unaudited Financial Results for the half year ended Sept 30, 2020

(₹. In Lakhs) (except per share data)

Sr. No.	Particulars	Quarter Ended			Six Months Ended		Year Ended
		Sept 30, 2020	June 30, 2020	Sept 30, 2019	Sept 30, 2020	Sept 30, 2019	Mar 31, 2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
(i)	Gross Revenue from sale of products and services	4,189.20	3,432.36	4,000.81	7,621.56	8,233.59	16,179.66
(ii)	Other operating revenue	136.21	147.88	202.61	284.09	380.46	941.95
1	REVENUE FROM OPERATIONS[(i)+(ii)]	4,325.41	3,580.24	4,203.42	7,905.65	8,614.05	17,121.61
2	Other Income	64.10	37.50	55.39	101.60	59.81	178.53
3	TOTAL INCOME (1+2)	4,389.51	3,617.74	4,258.81	8,007.25	8,673.86	17,300.14
4	EXPENSES						
a	Cost of materials Consumed	2,397.09	1,858.97	1,901.77	4,256.06	4,497.35	8,336.52
b	Changes in inventories	(196.04)	69.61	151.22	(126.43)	(260.85)	89.25
c	Employee benefits expense	800.02	636.73	767.13	1,436.75	1,464.29	2,920.05
d	Depreciation and amortization expense	287.87	283.40	233.64	571.27	452.03	1,105.94
e	Finance costs	4.38	4.37	5.81	8.75	11.62	23.14
f	Other expenses	858.77	614.73	740.73	1,473.50	1,585.57	3,134.60
	TOTAL EXPENSES	4,152.08	3,467.81	3,800.30	7,619.89	7,750.02	15,609.51
5	PROFIT BEFORE EXCEPTIONAL ITEMS AND TAX (3-4)	237.43	149.93	458.51	387.36	923.84	1,690.64
6	EXCEPTIONAL ITEMS	-	-	-	-	7,337.28	7,337.28
7	PROFIT BEFORE TAX (5-6)	237.43	149.93	458.51	387.36	(6,413.44)	(5,646.64)
8	Tax Expenses	-	-	-	-	-	-
9	PROFIT FOR THE PERIOD (7-8)	237.43	149.93	458.51	387.36	(6,413.44)	(5,646.64)
10	OTHER COMPREHENSIVE INCOME						
A(i)	Items that will not be reclassified to profit or loss	-	-	-	-	4,117.89	4,117.89
11	TOTAL COMPREHENSIVE INCOME (9+10)	237.43	149.93	458.51	387.36	(2,295.55)	(1,528.75)
12	PAID UP EQUITY SHARE CAPITAL (of Rs.2/- each)	2,378.71	2,378.71	2,378.71	2,378.71	2,378.71	2,378.71
13	OTHER EQUITY						(66,354.05)
	EARNINGS PER SHARE (of Rs 2/- each) (not annualised)						
a	Basic (Rs.)	0.20	0.13	0.39	0.33	0.78	1.42
b	Diluted (Rs.)	0.20	0.13	0.39	0.33	0.78	1.42

Sharon Bio - Medicine Limited
Statement of Assets & Liabilities as at September 30, 2020

(₹. In Lakhs)

Particulars	As at Sept 30, 2020	As at March 31, 2020
	Unaudited	Audited
ASSETS		
Non-current assets		
(a) Property, Plant and Equipment	14,218.99	14,645.58
(b) Capital work-in-progress	-	-
(c) Right to use of Assets	190.62	222.42
(d) Financial Assets		
(i) Loans & Advances	25.87	24.79
(e) Other Financial Assets	7.70	7.70
(f) Other non-current assets	857.71	843.27
	15,300.90	15,743.76
Current assets		
(a) Inventories	4,708.89	3,999.71
(b) Financial Assets		
(i) Trade receivables	2,569.78	2,216.71
(ii) Cash and cash equivalents	605.90	1,243.63
(iii) Bank balances other than (ii) above	1,909.69	1,909.69
(c) Other current assets	2,838.00	2,518.19
	12,632.25	11,887.93
TOTAL ASSETS	27,933.14	27,631.69
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	2,378.71	2,378.71
(b) Other equity	(65,966.69)	(66,354.05)
	(63,587.98)	(63,975.34)
Non-current liabilities		
(a) Financial Liabilities		
(i) Long term borrowings	55,801.72	55,801.72
(ii) Other financial liabilities	144.02	175.45
(b) Long term provisions	370.02	342.78
	56,315.76	56,319.96
Current liabilities		
(a) Financial Liabilities		
(i) Short term borrowings	26,930.68	26,930.68
(ii) Lease Liability -Current	58.53	54.19
(iii) Trade and other payables (MSME)	101.80	235.68
(iv) Trade and other payables	4,665.37	4,694.34
(v) Other financial liabilities	24.78	24.78
(b) Other current liabilities	3,359.13	3,282.33
(c) Short-term provisions	65.07	65.07
	35,205.36	35,287.07
	27,933.14	27,631.69

Sharon Bio - Medicine Limited
Cash Flow Statement For Period Ended Sept 30, 2020

₹ in Lakhs

Sr. No	Particulars	Period ended Sept 30, 2020		Year ended March 31, 2020	
A	Cash Flow From Operating Activities				
	Net Profit / (Loss) Before Tax		387.36		(5,646.65)
	Adjustments for :				
	Depreciation / amortisation	571.27		1,042.34	
	Loss/(Gain) on sale of fixed assets	-		-	
	Loss Allowances on Trade Receivables	(14.41)		17.07	
	Liability written back	-		(6.43)	
	Unrealised (gain) / loss on foreign exchange	38.90		45.49	
	Cash Flow from Exceptional Items	-		7,337.28	
	Interest Expense (Lease Asset)	8.75		21.88	
	Interest income	(23.72)		(58.73)	
	Loss on sale of MEIS	0.94		6.44	
	Sundry Write Off	-		-	
			581.72		8,405.35
	Operating Profit before working capital changes		969.08		2,758.70
	Adjustment for :				
	(Increase)/Decrease in Inventory	(709.17)		(1,151.23)	
	(Increase)/Decrease in Trade Receivables	(323.12)		(180.65)	
	Increase/(Decrease) in Trade Payables	(217.29)		258.75	
	Increase/(Decrease) in Other Current Liabilities	81.14		1,803.50	
	Increase/(Decrease) in Current Financial Liabilities	(40.13)		7.23	
	Increase/(Decrease) in Long Term Provisions	27.23		46.07	
	Increase/(Decrease) in Short Term Borrowings	-		-	
	Increase/(Decrease) in Short Term Provisions	-		9.78	
	Increase/(Decrease) in Short Term Loans & Adv	(1.08)		-	
	Increase/(Decrease) in Short Term Loans (Asset)	-		(0.18)	
	(Increase)/Decrease in Other Current Assets	(320.75)			
	(Increase)/Decrease in Other Non Current Assets	(14.44)		(64.58)	
			(1,517.60)		728.68
	Cash Generated From Operations		(548.52)		3,487.38
	Net Income Tax (paid) / refunds				17.92
	Net Cash Flow From / (used in) Operating Activities (A)		(548.52)		3,505.30
B	Cash Flow From Investing Activities				
	Purchase of Property, plant & Equipment (PPE)	(112.89)		(757.31)	
	Proceeds from sale of PPE/Capitalisation of PPE	-		-	
	Interest received	22.64		56.73	
			(90.25)		(700.58)
	Net Cash Flow From / (used in) Investing Activities (B)		(90.25)		(700.58)
C	Cash Flow From Financing Activities				
	Increase/(Decrease) in Borrowings Secured	-		-	
	Increase/(Decrease) in Other Financial Liabilities	-		-	
	(Increase)/Decrease in Other Financial Assets	1.08	1.08	(1.01)	(1.01)
	Net Cash Flow From / (used in) Financing Activities (C)		1.08		(1.01)
	Net Inc/(Dec) in Cash and Cash Equivalents (A+B+C)		(637.73)		2,803.65
	Cash and Cash Equivalents at the beginning of the year	3,153.32		349.67	
	Cash and Cash Equivalents at the end of the year	2,515.59		3,153.32	
			(637.73)		2,803.65
	Components of Cash & Cash Equivalents				
	Cash on Hand	1.14		4.56	
	Current Account	604.76		1,239.07	
	Unpaid Dividend Account (Earmarked)	12.78		12.78	
	Deposits & Bank Balance held as restricted use	1,896.91		1,896.91	
		2,515.59		3,153.32	

The accompanying notes form an integral part of this Balance Sheet

Notes:

- The Cash Flow Statement has been prepared under the Indirect Method as set out in the Indian Accounting Standard (IND AS 7)- Cash flow statement and presents cash flow by operating, investing and financing activities.
- The amendments to IND AS 7 Cash Flow Statements requires the entities to provide disclosures that enable users of financial statements to evaluate changes in liabilities arising from financing activities, including both the changes from cash flow and non-cash changes, suggesting including a reconciliation between the opening and closing balances in the Balance Sheet for liabilities arising from financing activities.
- Figures in the brackets are outflows/deductions
- Figures of the previous year have been regrouped/rearranged wherever necessary to make it comparable to the current year presentation

For Sharon Bio-Medicine Limited.

 Digitally signed
 by Kaushik
 Banerjee
 Date: 2020.11.11
 18:05:21 +05'30'

Kaushik Banerjee
CEO

 Digitally signed by Dinesh B
 Sharma
 DN: cn=Dinesh B Sharma, o=Sharon Bio-Medicine Limited, ou=Sharon Bio-Medicine Limited, email=dsharma@sharonbio.com, c=IN

Dinesh Sharma
VP-Finance

1. Sharon Bio-Medicine Limited, has undergone a corporate insolvency resolution process ("CIRP") under the aegis of the Insolvency and Bankruptcy Code, 2016 ("IBC"). The CIRP commenced on April 11, 2017 and culminated with the approval of a resolution plan by the National Company Law Tribunal ("NCLT"), Mumbai, vide its order dated March 8, 2018 in respect of the Company. The successful resolution applicant is Peter Beck und Partner Vermoögensverwaltung Ltd. ("Resolution Applicant"). The implementation of the Resolution Plan was challenged before the National Company Law Appellate Tribunal ("NCLAT") which saw it fit to dismiss the appeals and vacate its previous status quo order, vide its order dated December 19, 2018. Thereafter, the erstwhile promoters filed an appeal before the Supreme Court of India on February 5, 2019, which was dismissed by Supreme Court on April 5, 2019.
2. The resolution plan is not yet implemented as the Company is facing procedural delays to obtain necessary approvals from regulatory authorities, due to which:
 - a) No impact has been given in the financials in relation to the implementation of the resolution plan
 - b) The company assesses certain items based on the resolution plan which are likely to reduce loss and increase Other Equity by Rs 172.40 Cr based on the contractual cash flows. The impact of resolution plan based on discounted cash flows as per IND AS 109 could not be assessed due to pending implementation of resolution plan as at the reporting date. The impact on account of proposed settlement of creditors against their claims during CIRP, could not be assessed as it needs to be addressed case to case basis.
 - c) The Foreign Currency Convertible Bonds amounting to Rs. 169.69 Crores are considered to be part of Liabilities. The same is not bifurcated into debt and equity component as stipulated in IND AS 109. The Company is of the opinion that the same will be dealt in line with the Resolution Plan.
 - d) In accordance with IND AS 109, Loans liabilities shall be presented either as at amortised cost or as at fair value through profit or loss (FVTPL). However, term Loans amounting to Rs. 360.55 Cr are stated at cost, on account of pending implementation of the resolution plan as the amortised Cost and the effective interest rate is not ascertainable.
 - e) Pursuant to the Resolution Plan, the Resolution Applicants (RA) have infused a sum of Rs. 10.06 Crores, pending allotment within the stipulated time as per the Companies Act 2013. This amount has been disclosed under Other Current Liabilities as Share Application Money Pending Allotment.
3. Pending implementation of resolution plan, finance Cost & Interest on Statutory Dues has not been accrued during the quarter.
4. The above unaudited financial results are approved by Chief Executive Officer and Vice President Finance & Accounts in the meeting held on September 11, 2020.
5. Pending implementation of Resolution plan, management finds it impracticable to determine tax base of items of assets and liabilities and hence has not measured deferred tax assets and deferred tax liabilities as required by Ind AS 12.
6. The Company is in process of identification of parent assets and its components in the property plant and equipment, as required under Ind AS 16.

7. The process of identifying Cash Generating Units as required under Ind AS 36 for mandatory impairment testing shall be completed post implementation of the Resolution Plan.
8. The financial report has been prepared on a going concern based on the approval of the Resolution Plan by the adjudicating authority. The management has drawn detailed business plan which contemplates continuity of normal business activities and the realisation in the ordinary course of business. The business plan also contemplates by undertaking number of steps that enables the Company to raise meaningful funds and allow it to continue as a going concern.
9. The reporting of financial statement is for Pharmaceuticals segment. The company has no other segment that fulfils the quantitative threshold as specified under Ind AS - 108 "Operating Segments". Accordingly, segment reporting is not required.
10. In view of the continuing lockdown situation due to COVID-19 pandemic across the country, the Company has monitored the impact of COVID-19 on all aspects of its business, particularly for the financial year 2020-2021. There has been no significant impact on the business and profits of the Company for the year ended March 31, 2020. The Company is in manufacturing and sale of essential products. However, due to shortage of labour and manpower as well as the ambiguity for allowing operations, Company could not operate manufacturing activities for most part of first quarter and partially second quarter on all its manufacturing locations. As of date, manufacturing activities have reached near anticipated production and in execution of orders in hand, both domestic and exports.
11. The company has exercised due care, in concluding on significant accounting judgements and estimates, recoverability of receivables, assessment of inventory & other financial assets, based on internal & external information as available, up to the date of approval of these financial results. In view of the continued uncertainties and its inability to predict the extend and duration of Covid-19 situation, the impact assessed may be different from the estimates made as at the date of approval of these financial results and management will continue to monitor any material changes arising due to the impact of this pandemic on financial and operational performance of the company and take necessary measures to address the situation.
12. Previous year's/ quarter's figures have been re-grouped and re-arranged wherever considered necessary.

Place: Mumbai

Date: November 11, 2020

For Sharon Bio- Medicine Limited

**Kaushik
Banerjee**
Digitally signed
by Kaushik
Banerjee
Date: 2020.11.11
18:05:59 +05'30'
Kaushik Banerjee
Chief Executive Officer

**Dinesh B
Sharma**
Digitally signed by Dinesh B Sharma
DN: cn=Dinesh B Sharma, o=Sharon Bio-
Medicine Limited, email=dinesh@sharonbio.com,
c=IN
Date: 2020.11.11 17:59:46 +05'30'
Dinesh Sharma
VP- Finance



E A PATIL AND ASSOCIATES LLP

Chartered Accountants

316, Nirman Vyapar Kendra, Sector-17, Vashi, Navi Mumbai-400703 Maharashtra

Phone :02227668581, E-Mail : audit.exec@eapllp.in

**Independent Auditor's Limited Review Report on the quarterly and year to date
September 30, 2020 pursuant to the regulation 33 of the SEBI (Listing Obligation and
Disclosure Requirements) Regulations, 2015, as amended.**

To

Kaushik Banerjee

Chief Executive Officer

Sharon Bio-Medicine Limited

1. We have reviewed the accompanying statement of Unaudited Financial Results of Sharon Bio-Medicine Limited for the Quarter and year to date April 01, 2020 to September 30, 2020 (the statement) attached herewith , being submitted by the company pursuant to the requirements of Regulation 33 and 52 of the SEBI (Listing obligations and Disclosure Requirements) Regulations 2015, as amended (the "Listing Regulations").
2. This statement is the responsibility of the Company's Management and has been approved by the Chief Executive Officer, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards(Ind AS) specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and

Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. The company was under Corporate Insolvency Resolution Process (hereinafter referred as 'CIRP' or 'CIR Process') under Insolvency and Bankruptcy Code, 2016 (hereinafter referred as 'IBC' or 'the Code') with Mumbai Bench of National Company Law Tribunal (hereinafter referred as 'NCLT'). Consequently, the NCLT vide notification MA 12/2018 in CP No. 246/I&BP/NCLT/MAH/2017 under section 30(6) of IBC, 2016 has proposed certain settlements or restructuring plans of all claims based on the terms as mentioned in the resolution plan.
6. As per information and explanations given by the management, the impact of the approved settlement/restructuring plan on the financial statements has not been considered in the previous financial years 2017-18, 2018-19, 2019-20 as well as current quarter ending September 30, 2020. Attention is drawn to Note No 2 of Limited Review Report September 30th, 2020.
7. As per Section 134 of the Companies Act, 2013, the financial statements of a company are required to be authenticated by the chairperson of the board of directors, where authorized by the board or at least two directors, of which one shall be the managing director or the CEO (being a director), the CFO and the Company Secretary where they are appointed.

As the board is yet to be reconstituted post approval of restructuring plan by NCLT, the financial statements are being approved by Mr. Kaushik Banerjee, CEO of the Company appointed by the monitoring agency and the Company Secretary.

Emphasis of Matter

1. The Company as on September 30, 2020 has accumulated losses of Rs 78,021.64 Lakh (Excluding Share Premium and Revaluation Reserves) and its current liabilities exceeded its total assets by Rs 7272.22 Lakh. The financial results are drawn on going concern basis, considering the NCLT order referred in initial paragraph of the Limited Review Report statement.
2. Attention is drawn to Note No 2 & 3 of the Limited Review Report for non-implementation of resolution plan with respect to reinstatement of asset and liabilities & non-provision of Finance Cost and Interest on Statutory Dues which has not been accrued for the Financial Year 2017-18, 2018-19 & 2019-20 and Quarter ended September 30th, 2020.

Due to pending implementation of resolution plan, it is impracticable to determine the effect of effect resolution plan on the financial statement.

3. Departure with Indian Accounting Standards:
 - a. Attention is drawn to Note No.2 c in the Financial Statements; the Foreign Currency Convertible Bonds amounting to Rs.169.69 Crores are classified as Liabilities in the Financials. In accordance with IND AS 109, such bonds should

be split into debt and equity components. The classifications in the financials are a departure with the applicable Financial Reporting Framework.

- b. Attention is drawn to Note No. 2 d in the Financial Statements, Term Loans amounting to Rs. 360.55 Lakhs are not considered at amortized cost in accordance with IND AS 109.
- c. Attention is drawn to Note No.5 in the Financial Statements the Company for non-recognition of deferred tax assets & liabilities as per IND As 12.
- d. Attention is drawn to Note No.6 in the Financial Statements, the Company has not identified components in the Fixed Assets for want of component and its parent asset based information. This is not in line with the norms stipulated under IND AS 16 Property, Plant & Equipment.
- e. Attention is drawn to Note No.7 in the Financial Statements the Company has not conducted the mandatory impairment testing as required under IND AS 36 Impairment of Assets.

For M/s. E.A. Patil & Associates LLP
Chartered Accountants
Firm Registration No. 117371W / W100092

UJWAL NAGNATH LANDGE
LANDGE

Digitally signed by UJWAL
NAGNATH LANDGE
Date: 2020.11.11 17:14:37
+05'30'

CA. Ujwal N Landge
Partner
Membership No. 108231
Place: Vashi, Navi Mumbai
Date: November 11th, 2020
UDIN as per ICAI - 20108231AAAAFN5524